In newly diagnosed GBM, Optune® has a proven dose-response relationship over time.

In a clinical trial, Optune used at incrementally higher ratios of time increased the median OS benefit vs TMZ alone\(^1\)

<table>
<thead>
<tr>
<th>Percentage of Monthly Time on Optune</th>
<th>Median OS, months</th>
</tr>
</thead>
<tbody>
<tr>
<td>90%-100% (n=43) 22-24 hours/day(^1)</td>
<td>25 months (P&lt;0.05(^2))</td>
</tr>
<tr>
<td>70%-90% (n=257) 17-22 hours/day(^1)</td>
<td>22 months (P&lt;0.05(^2))</td>
</tr>
<tr>
<td>60%-70% (n=46) 14-17 hours/day(^1)</td>
<td>20 months (P&lt;0.05(^2))</td>
</tr>
<tr>
<td>50%-60% (n=42) 12-14 hours/day(^1)</td>
<td>18 months (P&lt;0.05(^2))</td>
</tr>
<tr>
<td>0% (n=229) TMZ alone</td>
<td>16 months</td>
</tr>
</tbody>
</table>

*Based on amount of time Optune was turned on and providing therapy over the course of a month. This data reflects the average patient usage of Optune for the first 6 months of treatment (months 1-6).\(^2\)

\(^1\)Approximation, based on monthly usage.

\(^2\)vs TMZ alone.

GBM, glioblastoma; OS, overall survival; TMZ, temozolomide.

**Indications For Use**

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).

Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery, and completion of radiation therapy together with concomitant standard of care chemotherapy.

Please see the Important Safety Information for Optune on the reverse side and the Optune Instructions For Use (IFU) for complete information regarding the device’s indications, contraindications, warnings, and precautions at Optune.com/IFU.
Optune® allows for flexible use that patients can readily adopt

Recommended usage is ≥75% of time
- Patients can benefit most from wearing Optune when turned on for 18 or more hours per day (≥75% of the time)
  - 75% of patients used Optune ≥75% of the time in the pivotal trial

Flexible use is available for various patient needs
- 50% daily use was the threshold for significant survival benefit over TMZ alone
  - 86% of patients received a survival benefit from Optune, because they used it more than half the time (n=388/450)

Flexible use with Optune

Threshold for significant survival benefit: 50% (12 hours/day)
Goal: 75% (18 hours/day)
Average daily Optune use
0% (24 hours/day)

Important Safety Information

Contraindications
Do not use Optune in patients with an active implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with implanted electronic devices has not been tested and may theoretically lead to malfunctioning of the implanted device. Use of Optune together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune ineffective.

Do not use Optune in patients that are known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions such as shock and respiratory failure.

Warnings and Precautions
Optune can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure™ (the device manufacturer).

Do not prescribe Optune for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune in these populations have not been established.

The most common (≥10%) adverse events involving Optune in combination with temozolomide were thrombocytopenia, nausea, constipation, vomiting, fatigue, medical device site reaction, headache, convulsions, and depression.

Use of Optune in patients with an inactive implanted medical device in the brain has not been studied for safety and effectiveness, and use of Optune in these patients could lead to tissue damage or lower the chance of Optune being effective.

If the patient has an underlying serious skin condition on the scalp, evaluate whether this may prevent or temporarily interfere with Optune treatment.

Please see the Optune Instructions For Use (IFU) for complete information regarding the device’s indications, contraindications, warnings, and precautions at Optune.com/IFU.